SWOG clinical trial number
SWOG-9505

Evaluation of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and No Prior Chemotherapy, Phase II

Closed
Phase
Accrual
55%
Published
Abbreviated Title
Evaluation of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and No Prior Chemotherapy, Phase II
Activated
01/01/1996
Closed
08/15/1997

Research committees

Melanoma

Publication Information Expand/Collapse

2008

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. [PMID18235113]

EL Korn;PY Liu;SJ Lee;JAW Chapman;D Niedzwiecki;VJ Suman;J Moon;VK Sondak;MB Atkins;EA Eisenhauer;W Parulekar;SN Markovic;S Saxman;JM Kirkwood Journal of Clinical Oncology 26(4):527-534

2002

A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy - Southwest Oncology Group study

RP Whitehead;JM Unger;LE Flaherty;EH Kraut;GM Mills;CE Klein;RA Chapman;GC Doolittle;N Hammond;VK Sondak Investigational New Drugs 20:105-111

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
91%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase